SCHEMBL20744447

SCHEMBL20744447

CC(C)c1cc(F)cc(-c2ccnc(N)c2)c1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 8/20 0.39
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
AAK1 Q2M2I8 2/20 0.37
MAPK14 Q16539 2/20 0.36
CIT O14578 1/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
KMT2A Q03164 1/20 0.36
GSK3B P49841 1/20 0.36
TLR9 Q9NR96 1/20 0.36
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29573583 0.88 ADORA2B (0.43) DYRK1AALOX5APFEN1HRH4AAK1
SCHEMBL23012692 0.88 ADORA2B (0.43) DYRK1AALOX5APFEN1HRH4AAK1
SCHEMBL20743706 0.87 TDO2 (0.39) DYRK1AHRH4AAK1TLR9TLR8
SCHEMBL30684113 0.87 TDO2 (0.39) DYRK1AHRH4AAK1TLR9TLR8
SCHEMBL20744379 0.86 ALOX5AP (0.36) ALOX5APFEN1HRH4MAPK14NLRP3
SCHEMBL21725517 0.84 ABL1 (0.42) DYRK1AALOX5APFEN1HRH4AAK1
SCHEMBL20744369 0.83 MAP4K4 (0.41) ALOX5APFEN1HRH4AAK1MAPK14
SCHEMBL20609796 0.83 NLRP3 (0.48) DYRK1AAAK1MAPK14MAPK13MAPK12
SCHEMBL20754538 0.83 MAP4K4 (0.41) ALOX5APFEN1HRH4AAK1TLR9
SCHEMBL20754870 0.83 HRH4 (0.40) DYRK1AALOX5APFEN1HRH4TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111132974-B Sulfonamide carboxamide compounds 英夫拉索姆有限公司 2023-11-21 CN disclosed
US-20200361895-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-11-19 US disclosed
US-20200361895-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-11-19 US disclosed
EP-3668861-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS Inflazome Limited (IE) 2020-06-24 EP disclosed
CN-111132974-A Novel sulfonamide carboxamide compounds 英夫拉索姆有限公司 2020-05-08 CN disclosed
WO-2019034686-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 WO disclosed
WO-2019034686-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361895-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 DYRK1A 2327/4885ALOX5AP 2410/4885FEN1 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.